Current and future therapy in Alzheimer's disease
- PMID: 18485144
- DOI: 10.1111/j.1472-8206.2008.00578.x
Current and future therapy in Alzheimer's disease
Abstract
Dementia is increasingly being recognized as one of the most important medical problems in the elderly. As most pharmacological research within the field of dementia is focused on Alzheimer's dementia (AD), this review will focus on pharmacological interventions in AD. Most disease-modifying therapies are based on the amyloid hypothesis. In this hypothesis, the pathological accumulation of Abeta in the brain leads to oxidative stress, neuronal destruction and finally the clinical syndrome of AD. Following this hypothesis, secondary prevention of AD can be made by: decreasing the production of Abeta, stimulation of clearance of Abeta formed or prevention of aggregation of Abeta into amyloid plaques. First a short overview on current approved therapies for AD is given. The main part of the review will focus on potential disease-modifying therapies for AD that are currently being studied in phase I to phase III trials.
Similar articles
-
[Therapy of Alzheimer disease].Neuropsychopharmacol Hung. 2009 Mar;11(1):27-33. Neuropsychopharmacol Hung. 2009. PMID: 19731816 Review. Hungarian.
-
Treatment of Alzheimer's disease: current and future therapeutic approaches.Rev Neurol Dis. 2004 Spring;1(2):60-9. Rev Neurol Dis. 2004. PMID: 16400259 Review.
-
Alzheimer's disease and the glutamate NMDA receptor.Psychopharmacol Bull. 2003 Spring;37(2):41-9. Psychopharmacol Bull. 2003. PMID: 14566213 Review.
-
Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives.Drug Discov Today. 2006 Oct;11(19-20):931-8. doi: 10.1016/j.drudis.2006.08.004. Epub 2006 Sep 7. Drug Discov Today. 2006. PMID: 16997144 Review.
-
Prevention of amyloid beta-induced memory impairment by fluvastatin, associated with the decrease in amyloid beta accumulation and oxidative stress in amyloid beta injection mouse model.Int J Mol Med. 2008 May;21(5):531-7. Int J Mol Med. 2008. PMID: 18425343
Cited by
-
Neuroprotective effects of sulforaphane on cholinergic neurons in mice with Alzheimer's disease-like lesions.Int J Mol Sci. 2014 Aug 18;15(8):14396-410. doi: 10.3390/ijms150814396. Int J Mol Sci. 2014. PMID: 25196440 Free PMC article.
-
Ashwagandha (Withania somnifera) reverses β-amyloid1-42 induced toxicity in human neuronal cells: implications in HIV-associated neurocognitive disorders (HAND).PLoS One. 2013 Oct 16;8(10):e77624. doi: 10.1371/journal.pone.0077624. eCollection 2013. PLoS One. 2013. PMID: 24147038 Free PMC article.
-
Novel anti-Alzheimer's dimer Bis(7)-cognitin: cellular and molecular mechanisms of neuroprotection through multiple targets.Neurotherapeutics. 2009 Jan;6(1):187-201. doi: 10.1016/j.nurt.2008.10.040. Neurotherapeutics. 2009. PMID: 19110209 Free PMC article. Review.
-
Chitosan Oligosaccharides Inhibit/Disaggregate Fibrils and Attenuate Amyloid β-Mediated Neurotoxicity.Int J Mol Sci. 2015 May 8;16(5):10526-36. doi: 10.3390/ijms160510526. Int J Mol Sci. 2015. PMID: 26006224 Free PMC article.
-
Therapeutic Potential of Multifunctional Tacrine Analogues.Curr Neuropharmacol. 2019;17(5):472-490. doi: 10.2174/1570159X16666180412091908. Curr Neuropharmacol. 2019. PMID: 29651948 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
